DB
Dawn Biopharma is a venture capital firm controlled by KKR, focusing on innovative medicines and therapies across the life sciences ecosystem. The firm's strategy involves providing flexible capital and strategic guidance to companies at various development stages, from early-stage to more mature businesses, that are developing novel treatments for significant unmet medical needs.
100% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deals in the last 12 months vs 2 prior). Average disclosed round size is $85.0M (across 3 rounds with reported amounts).
Portfolio
3
Fund Size
—
Top Stage
Seed
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
3 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Adcytherix | Series A | $105M | Oct 2025 |
 Adcendo ApS | Series B | $135M | Nov 2024 |
 Bambusa Therapeutics | Seed | $15M | Sep 2024 |
Top Co-Investors
Surveyor Capital2 shared
Pontifax2 shared
RA Capital Management2 shared
Lince Capital1 shared
Andera Partners1 shared
Angelini Ventures1 shared
Bpifrance1 shared
Kurma Partners1 shared
aMoon1 shared
Pureos Bioventures1 shared
OrbiMed1 shared
Logos Capital1 shared
Novo Holdings1 shared
HealthCap1 shared
Gilde Healthcare1 shared
Ysios Capital1 shared
Last updated: 10 April 2026